A ratio of the vancomycin area under the concentration-time curve to the MIC (AUC/MIC) of >400 has been associated with clinical success when treating Staphylococcus aureus pneumonia, and this target was recommended by recently published vancomycin therapeutic monitoring consensus guidelines for treating all serious S. aureus infections. Here, vancomycin serum trough levels and vancomycin AUC/MIC were evaluated in a "real-world" context by following a cohort of 182 patients with S. aureus bacteremia (SAB) and analyzing these parameters within the critical first 96 h of vancomycin therapy. The median vancomycin trough level at this time point was 19.5 mg/liter. There was a significant difference in vancomycin AUC/MIC when using broth microdilution (BMD) compared with Etest MIC (medians of 436.1 and 271.5, respectively; P < 0.001). Obtaining the recommended vancomycin target AUC/MIC of >400 using BMD was not associated with lower 30-day all-cause or attributable mortality from SAB (P ‫؍‬ 0.132 and P ‫؍‬ 0.273, respectively). However, an alternative vancomycin AUC/MIC of >373, derived using classification and regression tree analysis, was associated with reduced mortality (P ‫؍‬ 0.043) and remained significant in a multivariable model. This study demonstrated that we obtained vancomycin trough levels in the target therapeutic range early during the course of therapy and that obtaining a higher vancomycin AUC/MIC (in this case, >373) within 96 h was associated with reduced mortality. The MIC test method has a significant impact on vancomycin AUC/MIC estimation. Clinicians should be aware that the current target AUC/MIC of >400 was derived using the reference BMD method, so adjustments to this target need to be made when calculating AUC/MIC ratio using other MIC testing methods.
T
here are growing concerns about the ongoing utility of vancomycin in the treatment of serious Staphylococcus aureus infections due to increasing reports of suboptimal outcomes (1, 2) . While fully vancomycin-resistant S. aureus (VRSA) remains rare (3) , infections caused by vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA) may respond slowly or incompletely to vancomycin (4, 5) . Recently, new concerns have been raised about suboptimal responses to vancomycin if the MIC of the infecting organism lies at the upper end of the susceptible range (6, 7) , but this observation is not universal (8, 9) .
The pharmacodynamic parameter that is thought to best predict vancomycin efficacy is the ratio of the 24-hour area under the concentration-time curve to MIC (here referred to as AUC/MIC) (10) (11) (12) (13) . Recently, consensus guidelines were published in the United States to assist clinicians and pharmacists regarding vancomycin dosing strategies (14) . By attempting to bring consistency to therapeutic monitoring using the current state of knowledge about vancomycin pharmacodynamics and in view of potential problems of efficacy, relative resistance, and toxicity, these monitoring guidelines are intended to improve patient outcomes. These guidelines recommend a vancomycin target AUC/ MIC of Ն400 (14) but also note that this target attainment is difficult for isolates with vancomycin MICs of Ͼ1 mg/liter, and they go on to suggest that alternate agents may be required for therapy for infections with high vancomycin MICs (14) (15) (16) (17) (18) (19) (20) .
The serum AUC/MIC target value of Ն400 (using the 24-hour AUC) was originally derived by Moise et al. (21) in a retrospective study of methicillin-susceptible S. aureus (MSSA) and methicillinresistant S. aureus (MRSA) hospital-acquired pneumonia using classification and regression tree (CART) analysis. The investigators showed that an AUC/MIC of Ͼ345 predicted clinical cure, while a value of Ͼ866 predicted bacterial eradication from the lower respiratory tract. This study used a formula to estimate AUC that they validated separately in adults (22) . The published AUC formula, i.e., AUC ϭ total vancomycin dose in mg over 24 h/{[(CL CR ϫ 0.79) ϩ 15.4] ϫ 0.06} (22) , used the total daily dose of vancomycin divided by the renal creatinine clearance (CL CR ) calculated according to the Cockcroft-Gault equation (23) . The MIC was measured using the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution (BMD) method, and the AUC/MIC was reported using the average AUC/MIC calculated daily.
The consensus guidelines do not state whether the method of CL CR estimation for AUC or MIC determination has any impact on the calculated AUC/MIC and whether an AUC/MIC of Ն400 is applicable to other S. aureus infection syndromes and outcome measures, especially in a "real-world" clinical setting. We have recently investigated outcomes in a multicenter cohort of S. aureus bacteremia (SAB) patients and also have demonstrated an association between increasing vancomycin MIC and increased mortality. However, surprisingly, we found an association between increased mortality and high vancomycin MIC whether or not vancomycin was used for treatment (9) , which may mean that a high vancomycin MIC is a marker of some other patient or organism factor that is causally responsible for increased mortality. In this new study, we sought to evaluate the impact of different vancomycin MIC determination methods on AUC/MIC calculations and to determine if achieving a vancomycin AUC/MIC of Ն400 was associated with improved outcomes in patients from this cohort treated with vancomycin for SAB.
(This work was presented in part at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2011, abstr. A-1681 [46] .)
MATERIALS AND METHODS

Study population.
Patients for this observational study were vancomycin-treated patients from a previously described cohort (9) . Patients younger than 12 years were excluded from this pharmacodynamic analysis because the formula we used to estimate vancomycin AUC has been validated only in adults. The primary outcome measure was 30-day allcause mortality from the date of the first positive blood culture. Attributable 30-day mortality was also evaluated using previously published criteria (24) . Other endpoints assessed included persistent bacteremia (positive blood cultures at Ն7 days after the initial isolate) and recurrence of bacteremia within 30 days of the index positive blood culture (with documented negative blood cultures after the index positive blood culture). Duration of bacteremia was measured as the number of days from the index positive blood culture to the last positive blood culture obtained.
Data collection. Data for age, sex, onset of bacteremia, antibiotic treatment, and focus of S. aureus bacteremia infection were collected prospectively. However, additional clinical data required for this analysis were collected retrospectively using a detailed chart review. These included renal function, admission to an intensive care unit (ICU), Acute Physiology and Chronic Health Evaluation (APACHE) II score (25) , Simplified Acute Physiology Score (SAPS) II (26), Charlson weighted index of comorbidity (CWI) (27) , Pitt bacteremia score (28) , vancomycin dosing regimens during the first 28 days of treatment, and serum vancomycin levels. Illness severity scores were calculated as the worst values within 48 h prior to the onset of SAB (measured as the time of collection of the index positive blood culture) (29) . The following comorbidities were also collected: heart disease (ischemic heart disease, congestive cardiac failure, or cardiac arrhythmia requiring implantable electronic device), diabetes mellitus, dialysis (established peritoneal or hemodialysis), malignancy (solid organ or hematologic), transplant (solid organ or hematologic), immunosuppression (receipt of chemotherapy, monoclonal antibody, immunomodulation, or corticosteroids equivalent to prednisolone at 20 mg or more per day in the 30 days prior to SAB onset), liver disease (chronic liver disease or cirrhosis), dementia, and active injecting drug use (IDU). Contemporaneous local dosing guidelines recommended initial dosing of vancomycin at 25 mg/kg every 12 h in adult patients with normal renal function (30) with subsequent dose adjustment according to vancomycin serum trough levels, although individual regimens were ultimately decided by treating physicians. Compliance with these recommendations was not assessed. As this was an observational study, vancomycin levels were determined at the discretion of treating physicians. Trough levels (or spot levels for patients on hemodialysis) were generally obtained 24 to 96 h after commencement of vancomycin. Target trough levels according to local guidelines (30) were 10 to 20 mg/liter, although there was variability in recommended targets at different institutions; modifications of vancomycin doses were made by individual treating physicians. The number of vancomycin levels obtained for each patient during treatment varied according to the number of dose adjustments, fluctuating renal function, alteration in clinical status, or at the judgment of treating clinicians.
Microbiological data. The first positive blood culture isolate from each patient was stored at Ϫ80°C until undergoing detailed microbiological testing. This included vancomycin MIC determination using BMD (31) and Etest (bioMérieux, Marcy l'Etoile, France). Screening for hVISA was performed using the Glycopeptide Resistance Detection (GRD) Etest (bioMérieux, Marcy l'Etoile, France).
Vancomycin pharmacodynamic data. Renal function was estimated using two commonly used formulae: the "175" Modification of Diet in Renal Disease (MDRD) formula, which is an isotope dilution mass spectrometry (IDMS)-aligned equation that provides an estimated glomerular filtration rate (eGFR), i.e., MDRD (23) . There is no correction for African-American race in the MDRD equation used in Australia and New Zealand, reflecting the low prevalence of this group in the Australasian population (33) . The MDRD eGFR is automatically reported alongside serum creatinine results in most Australasian laboratories. The 24-hour vancomycin AUC was calculated using the formula AUC ϭ total vancomycin dose in mg over 24 h/{[(CL CR ϫ 0.79) ϩ 15.4] ϫ 0.06} and has been employed by other authors (34, 35) . Timely achievement of therapeutic serum vancomycin levels is critical in the treatment of bacteremia, so we specifically evaluated the vancomycin AUC within the first 96 h of treatment. The total vancomycin daily dose over 24 h used in the formula corresponded to the vancomycin dose at the time of first available vancomycin trough level for each patient, taken within 96 h of vancomycin commencement. Actual body weight (where available) was used for the Cockcroft-Gault equation. The AUC/MIC was calculated using both MIC methods.
Statistical analysis. The relationship between AUC/MIC and 30-day mortality was explored both as a categorical variable and as a continuous variable. For categorical analysis, both a two-group analysis and a threegroup analysis were performed using classification and regression tree (CART) analysis to account for potential nonlinearity and nonmonotonicity, respectively. For continuous univariable analysis, the AUC/MIC was fitted by nonlinear regression to a standard exposure-response (Hill) curve. Multivariable logistic regression was performed to identify factors associated with 30-day mortality and to test the strength of the association between AUC/MIC and outcome. The recommended target AUC/MIC (Ն400) and the CART-derived two-group AUC/MIC cutoff (Academic CART Pro v6.6; Salford Systems, San Diego, CA) were both used to create a dichotomous AUC/MIC variable for multivariable regression. Similarly for multivariable analysis, continuous data such as age and disease or illness severity markers were converted into dichotomous variables for logistic regression using cutoffs associated with poor clinical outcomes from previously published studies. The 2 test or Fisher exact test was used to compare categorical variables, and the Mann-Whitney test was used for continuous nonparametric variables. Kaplan-Meier survival curves were constructed, and the log rank test was used to compare the curves. Multivariable logistic regression was performed to identify factors associated with 30-day mortality, with goodness of fit of the final model evaluated with the Hosmer-Lemeshow statistic. Analyses were performed using GraphPad Prism v5.0 (GraphPad Software, San Diego, CA), Stata v11.1 (StataCorp, College Station, TX), and R v2.15.2 (http://www.r-project .org/).
Ethics. Human ethics committee approval was obtained at each of the participating sites.
RESULTS
Demographics.
Clinical and drug dosing data were available for 186 vancomycin-treated patients from our original cohort. Four of these patients were excluded (1 patient, 30-day outcome not recorded; 3 patients, Ͻ12 years), leaving 182 patients for final analysis. Table 1 shows patient demographics according to 30-day Patients achieving a vancomycin AUC/MIC of Ն400 were more likely to be older and have diabetes or a requirement for permanent dialysis. The median duration of bacteremia was 1 day (range, 1 to 18 days), and rates of persistent or recurrent bacteremia in survivors and in nonsurvivors were similar. Documentation of patient weight was obtained for only 99 patients; in this subset, the median weight was 71 kg (interquartile range [IQR], 61 to 90 kg), and there was no statistical difference between survivors and nonsurvivors (P ϭ 0.673). Acute renal failure was present in almost one-quarter of patients at onset of SAB. Vancomycin trough levels. One or more vancomycin trough levels were obtained for 165 patients (90.7%) within 96 h of commencing treatment. The number of vancomycin levels per patient obtained within this time period varied, mainly due to differences in vancomycin dosing frequency. To account for these differences, we evaluated those patients with vancomycin trough levels obtained at 96 h after commencement (n ϭ 102), which approximates the earliest time of near steady state in a patient with normal renal function receiving daily vancomycin dosing (before the fourth dose). The median vancomycin trough at this time was 19.5 mg/liter (interquartile range, 15.0 to 24.0 mg/liter). Table 2 shows measured vancomycin trough levels at 96 h according to methicillin susceptibility, vancomycin MIC, and 30-day outcome.
Vancomycin susceptibility. The distribution of vancomycin MICs of the isolates determined by both Etest and BMD is shown in Table 3 and demonstrates important differences in MIC between the two methods. The modal MIC was 1 mg/liter by BMD (78.6%) and 1.5 mg/liter by Etest (41.2%). Others have also noted higher MIC values with Etest than with BMD (36-39). All isolates were considered susceptible according to the CLSI reference BMD method (31), but one isolate (0.6%) demonstrated vancomycin heteroresistance using the Etest GRD.
Effect of CL CR calculation on vancomycin AUC. The eGFR obtained using the MDRD formula was reported for all 182 patients; however, the estimated CL CR obtained using the CockcroftGault equation was calculated for only the 99 patients for whom weight was documented. The MDRD formula tended to yield higher values of CL CR (median, 50.6; IQR, 23.7 to 81.3) than the Cockcroft-Gault equation (median 34.3, IQR 18.2 to 92.2); however, the difference in medians was not statistically significant (P ϭ 0.468). The calculated vancomycin AUCs using both these CL CR estimates were similar (MDRD median, 416.2; CockcroftGault median, 428.0; P ϭ 0.850).
Effect of MIC test method on vancomycin AUC/MIC. The vancomycin AUC/MIC was calculated using the MDRD and Cockcroft-Gault formulae for CL CR and BMD and Etest for MIC (see Table S1 in the supplemental material). As there was no significant difference in AUC calculation using either the MDRD formula or the Cockcroft-Gault equation, we chose to use the MDRD formula for CL CR as more data points were available for further analysis. The median vancomycin AUC/MIC was different using BMD and Etest (BMD median, 436. Table S1 in the supplemental material]). The very high AUC/MIC was calculated in one patient with chronic kidney disease (serum creatinine, 447 mol/liter) whose blood culture isolate had a very low vancomycin MIC (0.25 mg/liter). The calculated vancomycin AUC/MIC was significantly higher when using the BMD MIC than with the Etest MIC (P Ͻ 0.001). Figure 1 shows a scattergram of log-transformed vancomycin AUC/MIC using BMD versus Etest. This demonstrates that there is a clear difference in AUC/MIC values according to MIC method and that the target AUC/MIC of Ն400 is MIC method dependent. Using a line of best fit derived by linear regression, the equivalent AUC/MIC using the MIC observed by BMD of 400 is 226 using the MIC observed by Etest in our cohort.
Effect of target AUC/MIC attainment on mortality in patients with SAB. Figure 2 shows the vancomycin AUC/MIC from each patient according to survivors versus nonsurvivors. The distributions of values around the target vancomycin AUC/MIC of 400 using BMD are similar in survivors and nonsurvivors (P ϭ 0.296), with a significant number of survivors (62/144, 43.1%) failing to achieve this target. The proportion of survivors with a vancomycin AUC/MIC of Ͻ400 using BMD did not change if patients with peripheral or central intravenous catheter-associated infection were excluded (37/91, 40.7%), and there was a similar proportion of survivors failing to achieve a vancomycin AUC/MIC ratio of 226 using Etest (47/144, 32.60%).
Patients were then divided into two groups according to whether they achieved the published target vancomycin AUC/ MIC of Ն400 using BMD MIC values (14, 22) . Figure 3B shows the proportion of survivors according to attainment or failure to achieve the target vancomycin AUC/MIC of Ն400, and there was no significant difference between the two groups (P ϭ 0.203). The Kaplan-Meier survival curve for 30-day all-cause mortality (Fig. 3C) shows an early small divergence in the curves; however, there was no statistical difference in survival (log rank test, P ϭ 0.132) in patients who did not achieve the pharmacodynamic target vancomycin AUC/MIC of Ն400 using BMD MIC compared with those who did. In addition, there was no difference in survival when analyzing according to 30-day attributable mortality (P ϭ 0.273) or adjusting for methicillin susceptibility (see Table S2 in the supplemental material).
Using CART, a breakpoint for 30-day all-cause mortality using BMD was identified for the vancomycin AUC/MIC at 373. The probability of survival was 71.6% for those with a vancomycin AUC/MIC of Յ373, compared with 84.3% for those patients with a vancomycin AUC/MIC of Ͼ373. There was a statistically significant difference in all-cause mortality using this CART-derived vancomycin AUC/MIC (P ϭ 0.043). Using the mortality difference between these two groups as a point estimate for absolute risk reduction (12.7%), the number needed to treat was 8 (compared with 14 for the predefined vancomycin AUC/MIC cutoff of 400). There were no major differences in baseline patient demographics according to the CART-derived vancomycin AUC/MIC target of 373 compared with those reported in Table 1 for the target of 400 (see Table S3 in the supplemental material). Figure 3D demonstrates the proportion of survivors according to attainment of the CART-derived vancomycin AUC/MIC of Ͼ373 (P ϭ 0.043), and Fig. 3E shows the Kaplan-Meier survival curve using the CARTderived target (log rank test, P ϭ 0.043). Among survivors, there was still a significant proportion (53/144, 36.8%) who failed to achieve a vancomycin AUC/MIC of Ͼ373. There was no difference in mortality when adjusted for methicillin susceptibility (see Table S4 in the supplemental material). The CART-derived cutoff for Etest was 130 (P ϭ 0.005 for 30-day all-cause mortality).
We also analyzed the vancomycin AUC/MIC using BMD according to vancomycin MIC group, given our previously demonstrated association between elevated vancomycin MIC and 30-day mortality. Figure 4 shows a dot plot of vancomycin AUC/MIC 6%], respectively; P ϭ 1.000). When using the CART-derived AUC/MIC target of Ͼ373, there were also no statistical differences between these two groups (low versus elevated vancomycin MIC, P ϭ 0.880; MSSA versus MRSA, P ϭ 1.000). We found no association between achieving a vancomycin AUC/ MIC of Ն400 (published target) or Ͼ373 (our CART-derived target) and reduction in other secondary outcome measures such as attributable mortality (Ն400, P ϭ 0.273; Ͼ373, P ϭ 0.115), persistent bacteremia (Ն400, P ϭ 0.649; Ͼ373, P ϭ 1.000), or recurrent bacteremia (Ն400, P ϭ 0.654; Ͼ373, P ϭ 0.817). Among nonsurvivors, the proportions of patients achieving a vancomycin AUC/MIC of Ն400 in attributable versus nonattributable deaths were similar (10/23 versus 7/15, respectively; P ϭ 1.000). We also analyzed different target AUC/MIC cutoffs reported in various studies (AUC/ MIC BMD of Ͼ345 [21] , AUC/MIC BMD of Ͼ866 for bacterial eradication [21] , AUC/MIC Etest of Ͼ211 [40] , and AUC/MIC BMD of Ͼ421 [41] ) and found no statistical difference in 30-day outcome according to achievement of these targets.
Relationship between vancomycin trough level and vancomycin AUC. As the formula used to calculate vancomycin AUC, i.e., AUC ϭ total vancomycin dose in mg over 24h/{[(CL CR ϫ 0.79) ϩ 15.4] ϫ 0.06}, did not include measured vancomycin trough levels from patients, we also assessed the relationship between vancomycin trough levels measured within 96 h of treatment commencement and vancomycin AUC. There was only a moderate correlation between measured vancomycin trough levels and calculated vancomycin AUC (r ϭ 0.246, P ϭ 0.002).
Multivariable analysis. Variables identified as potentially significant on univariable analysis (P Ͻ 0.2) were considered for inclusion into a multivariable model to establish risk factors for 30-day mortality. For correlated variables (for example, age and APACHE II score), only one was included in multivariable analysis. Do-not-resuscitate (DNR) orders were specifically excluded from this model as these lead to modifications or withdrawal of treatment that have a direct impact on clinical outcome. Using multivariable logistic regression, variables that were independently associated with increased 30-day mortality in SAB were age of Ն70 years, sepsis syndrome, and a Pitt bacteremia score of Ն4, whereas a vancomycin AUC/MIC of Ͼ373 was protective (Table 4 ) (Hosmer-Lemeshow statistic for final model, P ϭ 0.089).
DISCUSSION
There is an accepted association between poorer outcomes in S. aureus infections and an elevated vancomycin MIC within the susceptible range (6), leading some to question the ongoing value of vancomycin in the treatment of serious S. aureus infections (1). Higher vancomycin doses have been recommended to optimize outcomes but at the price of increased nephrotoxicity (42) . The most precise pharmacodynamic predictor of outcome is thought to be the vancomycin AUC/MIC, and it is considered to be more accurate than related measures such as time above MIC and the peak/MIC ratio in in vitro, animal, and small human studies (10) (11) (12) (13) 22) . Acknowledging that comprehensive clinical data are lacking, consensus guidelines (14) for vancomycin dosing and monitoring recommend a number of strategies intended to optimize outcomes, minimize toxicity, and prevent the development of resistance. Key recommendations are to achieve vancomycin serum trough levels of 15 to 20 mg/liter and an AUC/MIC of Ն400. This ratio was originally derived from patients with staphylococcal pneumonia, using the BMD method for MIC determination and a formula based on vancomycin dosing and CL CR for AUC (21, 22) and evaluating clinical success. In this study, we evaluated the usefulness of the AUC/MIC of Ն400 in patients with staphylococcal bacteremia. We also assessed the impact of two different methods of MIC determination on AUC/MIC calculations and then sought to determine if achieving a vancomycin AUC/MIC of Ն400 with the BMD method within the first critical 96 h of therapy resulted in reduced mortality in our cohort of patients with S. aureus bacteremia.
Not surprisingly we found that calculation of the vancomycin AUC/MIC is MIC method dependent, so clinicians need to be aware of this and specify the methods used to obtain MIC values when aiming for particular AUC/MIC targets. An Etest MIC is often higher than that with the BMD methodology (9, (36) (37) (38) 43) . We suspect that this is the result of an inoculum effect (the inoculum is higher with Etest), which has been observed in vivo (44) . As a result, the vancomycin AUC/MIC is significantly lower when using Etest MIC than when using the BMD MIC. If the Etest is used to measure MIC, then we have calculated that the equivalent AUC/MIC target should be 226 rather than 400 using our linear regression model. Vancomycin AUC measurement may also vary according to the method used for its estimation. Although the MDRD formula was developed as a tool for evaluation of chronic kidney disease and may underestimate renal clearance in healthy individuals (45), we showed that differences in CL CR calculation using the MDRD and Cockcroft-Gault formulae have little influence on vancomycin AUC estimates using the formula published by Moise-Broder et al. (22) . With these caveats in mind, we then investigated the prognostic value of the recommended vancomycin AUC/MIC of Ն400 as determined by BMD in our cohort of patients with S. aureus bacteremia in a "real-world" setting. Target vancomycin trough levels were achieved early in the vancomycin treatment course (within 96 h), potentially maximizing vancomycin efficacy. While there was a gradual rise in the proportion of survivors as the vancomycin AUC/MIC increased, there was no clear cutoff associated with improved survival (Fig. 2 and Fig. 3A) . The a priori defined vancomycin AUC/MIC of Ն400 obtained within 96 h of therapy was associated with a calculated 8% reduction in mortality, but this was not a statistically useful predictor of outcome. However, when we moved away from an a priori definition and used CART analysis to establish a new AUC/MIC cutoff, we did find a statistically significant association between achieving a vancomycin AUC/ MIC of Ͼ373 within the first 96 h of vancomycin therapy and reduced 30-day mortality. Patients who achieved an AUC/MIC of Ͼ373 had a 12% lower mortality than those who did not (P ϭ 0.04). The CART-derived value is in fact closer to the original vancomycin AUC/MIC of 345 reported by Moise et al. (21) , upon which the target of 400 was established. While it makes biological and clinical sense that higher vancomycin AUC/MIC ratios directly improve patient outcomes, we caution that the relationship may be more complex than this, particularly as our previous study (9) demonstrated that a high vancomycin MIC was associated with increased mortality even in patients who were not treated with vancomycin. We believe that multiple factors apart from the vancomycin AUC/MIC influence outcome, including strain-specific genotypic and virulence differences and the host-organism interaction. Even using the new cutoff of 373 that we obtained with CART, almost 90% of the survival difference between patients is likely to be explained by factors other than the AUC/MIC itself.
Other studies have examined vancomycin AUC or AUC/MIC but they describe a variety of different infection syndromes and outcome measures. In their original paper describing the vancomycin AUC/MIC, Moise et al. (21) (41) studied 320 patients with MRSA bacteremia using a composite endpoint of treatment failure (30-day mortality, persistent symptoms and signs of infection, and persistent bacteremia for Ն7 days). Both BMD and Etest MIC determinations were performed. Using CART analysis, an AUC/MIC of Ͻ421 (presumably using BMD) was associated with treatment failure. Interestingly, high rates of persistent bacteremia (127/168) were noted, and the median AUC/MIC values with treatment success versus failure were similar (587 and 537, respectively).
There are several limitations to our study. Information about surgical debridement or removal of devices was not obtained, and we were unable to ascertain compliance with local vancomycin dosing guidelines or to assess rates of nephrotoxicity. Due to widely varying dosage schedules, we did not account for expected differences in trough levels depending on dosing frequency. The vancomycin AUC was calculated with a simple formula based on daily vancomycin dose and renal function; however, this does not take into consideration the measured serum vancomycin levels obtained from patients. This is an accepted method for AUC/MIC estimation; however, more sophisticated computer-based programs may be able to improve AUC estimation. Our study also included patients with a wide variety of infective processes associated with bacteremia, including a proportion that were likely to have good outcomes, such as those with skin and skin structure infection or line sepsis who had the device removed early. Nevertheless, our study suggests that refinements need to be made to recommendations for AUC/MIC target attainment in treatment of S. aureus bacteremia. The heterogeneous nature of our results and those from other studies raises the suspicion that the relationship between vancomycin AUC and MIC may be different according to infection type or site and outcome measure. In particular infections associated with high bacterial loads may be a particular problem, as a true inoculum effect with vancomycin has been demonstrated (44) . Previous studies have evaluated the average daily vancomycin AUC/MIC at steady state during a course of vancomycin treatment (22, 40) , whereas we have focused on assessing the vancomycin AUC/MIC achieved within the first 96 h of vancomycin therapy. We believe that this is a clinically relevant endpoint and may provide clinicians with an alternative measure of efficacy in addition to monitoring vancomycin trough levels during the early stages of treatment for SAB.
The optimum vancomycin AUC/MIC using non-BMD MIC methods has not been established. Therefore, clinicians using pharmacodynamic targets to guide vancomycin therapy for serious S. aureus infections need to be alert to the method of MIC determination in their own laboratories when calculating the vancomycin AUC/MIC, as this will influence the numerical target. Improved algorithms for AUC calculation that include actual measured serum vancomycin levels may be beneficial. Further research into the generalizability of AUC/MIC targets in different S. aureus infection syndromes and outcome measures is required. Appropriate vancomycin dosing to achieve serum trough levels within the target therapeutic range early in the treatment course is also important, and management should also take the clinical status of the patient into consideration. Achieving a vancomycin AUC/MIC that approximates the target of Ն400 rapidly during the early treatment of SAB is associated with improved survival; however, this effect is small, and survival is likely to be heavily dependent on other, as-yet-unknown host and organism characteristics.
